Human Serum Albumin Takeda

Human Serum Albumin Takeda is a sterile intravenous solution containing human serum albumin, a plasma protein used in clinical practice. It is supplied in a liquid form for infusion into the bloodstream under medical supervision. The product is manufactured for the European market and is available by prescription only. It provides exogenous albumin to support plasma oncotic pressure and volume status in selected patients today.

Human Serum Albumin Takeda is employed in clinical settings where restoration of plasma volume or oncotic pressure is required. It is typically considered for patients with conditions that lead to low albumin levels or fluid shifts.

- Management of hypoalbuminemia associated with liver disease, malnutrition, or chronic illness - Support of circulatory volume in severe burns, major trauma, or extensive fluid loss - Adjunct therapy during major surgery to maintain intravascular volume and hemodynamic stability - Treatment of nephrotic syndrome with significant protein loss to reduce edema - Correction of hypovolemia in septic shock when endogenous albumin is depleted - Use in acute respiratory distress syndrome to improve oncotic balance and pulmonary fluid dynamics

Human Serum Albumin Takeda may be associated with a range of adverse reactions, varying from mild to severe.

Common: - Mild flushing or sensation of warmth at the infusion site, usually brief - Headache of low to moderate intensity during or shortly after infusion - Nausea or mild gastrointestinal discomfort that resolves without intervention - Transient low‑grade fever or chills occurring within the first hour of administration

Serious: - Severe allergic reaction such as anaphylaxis requiring immediate medical attention - Pronounced hypersensitivity manifesting as rash, urticaria, or angioedema - Pulmonary edema or fluid overload, especially in patients with cardiac compromise - Thromboembolic complications including deep vein thrombosis or pulmonary embolism

When prescribing Human Serum Albumin Takeda, clinicians should consider several precautionary measures to minimize risk and ensure appropriate use.

- Assess cardiac and renal function before infusion, as volume expansion may exacerbate heart failure or renal impairment - Monitor fluid balance and weight during treatment to detect signs of overload - Use caution in patients with known hypersensitivity to albumin or blood‑derived products - Consider the unknown pregnancy category; avoid use unless potential benefit justifies potential risk - Observe for signs of infection or sepsis, as albumin can affect vascular permeability - Adjust dosage in patients with severe hypoalbuminemia or rapid fluid shifts, following clinical judgment - Discontinue infusion promptly if any serious adverse reaction occurs

Human Serum Albumin Takeda can interact with other medications or clinical conditions, influencing its safety or efficacy.

Avoid: - Concurrent administration of other volume expanders (e.g., crystalloids, synthetic colloids) that may cause excessive fluid overload - Use with drugs that have a narrow therapeutic window and are highly protein‑bound, as albumin may alter their free concentrations - Simultaneous infusion of blood products that increase the risk of immunologic reactions

Use with caution: - Diuretics, which may mask fluid balance changes and require closer monitoring - Vasopressor agents, where rapid plasma volume changes can affect hemodynamic response - Anticoagulants, as altered plasma volume may influence coagulation parameters